Furthermore, etomoxir, an inhibitor of CPT1A that was clinically used for tackling type 2 diabetes and heart failure, yet was withdrawn owing to severe hepatotoxicity, has been identified as reducing the activation of caspase-1, and the secretion of IL-1β and IL-18, in vitro, when encountering nigericin and ATP [135,153,154]. Here, IL18 is linked to type 2 diabetes mellitus.